SAREPTA THERAPEUTICS INC (SRPT) Fundamental Analysis & Valuation

NASDAQ:SRPT • US8036071004

Current stock price

20.64 USD
-0.04 (-0.19%)
At close:
20.52 USD
-0.12 (-0.58%)
After Hours:

This SRPT fundamental analysis includes valuation metrics, fair value assessment, financial health analysis, profitability trends, growth metrics and dividend sustainability analysis.

1

1. SRPT Profitability Analysis

1.1 Basic Checks

  • SRPT had negative earnings in the past year.
  • In the past year SRPT has reported a negative cash flow from operations.
  • In the past 5 years SRPT reported 4 times negative net income.
  • In the past 5 years SRPT always reported negative operating cash flow.
SRPT Yearly Net Income VS EBIT VS OCF VS FCFSRPT Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 0 200M -200M -400M -600M

1.2 Ratios

  • SRPT has a Return On Assets of -21.30%. This is in the better half of the industry: SRPT outperforms 74.61% of its industry peers.
  • With a Return On Equity value of -62.55%, SRPT perfoms like the industry average, outperforming 55.43% of the companies in the same industry.
Industry RankSector Rank
ROA -21.3%
ROE -62.55%
ROIC N/A
ROA(3y)-10.59%
ROA(5y)-13.51%
ROE(3y)-36.51%
ROE(5y)-67.48%
ROIC(3y)N/A
ROIC(5y)N/A
SRPT Yearly ROA, ROE, ROICSRPT Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 0 -50 -100 -150

1.3 Margins

  • SRPT has a better Gross Margin (69.33%) than 79.84% of its industry peers.
  • In the last couple of years the Gross Margin of SRPT has declined.
  • SRPT does not have Profit Margin and Operating Margin available, so we won't be analyzing them here.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM 69.33%
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y-6.57%
GM growth 5Y-4.72%
SRPT Yearly Profit, Operating, Gross MarginsSRPT Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 0 -1K -2K -3K -4K

More info and screens

ROAROEROICOperating and Profit MarginShow most profitable peers

2

2. SRPT Health Analysis

2.1 Basic Checks

  • SRPT does not have a ROIC to compare to the WACC, probably because it is not profitable.
  • The number of shares outstanding for SRPT has been increased compared to 1 year ago.
  • Compared to 5 years ago, SRPT has more shares outstanding
  • The debt/assets ratio for SRPT has been reduced compared to a year ago.
SRPT Yearly Shares OutstandingSRPT Yearly Shares OutstandingYearly Shares Outstanding 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 20M 40M 60M 80M 100M
SRPT Yearly Total Debt VS Total AssetsSRPT Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 1B 2B 3B

2.2 Solvency

  • SRPT has an Altman-Z score of -0.76. This is a bad value and indicates that SRPT is not financially healthy and even has some risk of bankruptcy.
  • With a Altman-Z score value of -0.76, SRPT perfoms like the industry average, outperforming 53.29% of the companies in the same industry.
  • SRPT has a Debt/Equity ratio of 0.73. This is a neutral value indicating SRPT is somewhat dependend on debt financing.
  • Looking at the Debt to Equity ratio, with a value of 0.73, SRPT is doing worse than 73.06% of the companies in the same industry.
Industry RankSector Rank
Debt/Equity 0.73
Debt/FCF N/A
Altman-Z -0.76
ROIC/WACCN/A
WACC8.47%
SRPT Yearly LT Debt VS Equity VS FCFSRPT Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 0 500M -500M 1B 1.5B

2.3 Liquidity

  • SRPT has a Current Ratio of 2.32. This indicates that SRPT is financially healthy and has no problem in meeting its short term obligations.
  • SRPT's Current ratio of 2.32 is on the low side compared to the rest of the industry. SRPT is outperformed by 74.61% of its industry peers.
  • A Quick Ratio of 1.48 indicates that SRPT should not have too much problems paying its short term obligations.
  • Looking at the Quick ratio, with a value of 1.48, SRPT is doing worse than 81.78% of the companies in the same industry.
Industry RankSector Rank
Current Ratio 2.32
Quick Ratio 1.48
SRPT Yearly Current Assets VS Current LiabilitesSRPT Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 1B 2B 3B

More info and screens

WACCDebt/EquityHow to determine the health of a companyAltman-Z scoreShow peers with great health

4

3. SRPT Growth Analysis

3.1 Past

  • The earnings per share for SRPT have decreased strongly by -391.67% in the last year.
  • The Revenue has grown by 15.58% in the past year. This is quite good.
  • SRPT shows a strong growth in Revenue. Measured over the last years, the Revenue has been growing by 32.41% yearly.
EPS 1Y (TTM)-391.67%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-362%
Revenue 1Y (TTM)15.58%
Revenue growth 3Y33.07%
Revenue growth 5Y32.41%
Sales Q2Q%-32.73%

3.2 Future

  • Based on estimates for the next years, SRPT will show a very strong growth in Earnings Per Share. The EPS will grow by 20.10% on average per year.
  • The Revenue is expected to decrease by -7.26% on average over the next years.
EPS Next Y147.03%
EPS Next 2Y50.1%
EPS Next 3Y29.84%
EPS Next 5Y20.1%
Revenue Next Year-18.84%
Revenue Next 2Y-17.93%
Revenue Next 3Y-12.16%
Revenue Next 5Y-7.26%

3.3 Evolution

  • The Revenue growth rate is decreasing: in the next years the growth will be less than in the last years.
SRPT Yearly Revenue VS EstimatesSRPT Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2015 2017 2019 2021 2023 2025 2027 2029 2031 2033 500M 1B 1.5B 2B
SRPT Yearly EPS VS EstimatesSRPT Yearly EPS VS EstimatesYearly EPS VS Estimates 2015 2017 2019 2021 2023 2025 2027 2029 2031 2033 0 2 -2 -4 -6 -8

More info and screens

Find the best growth stocksShow best growing peers

4

4. SRPT Valuation Analysis

4.1 Price/Earnings Ratio

  • SRPT reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.
  • Based on the Price/Forward Earnings ratio of 6.60, the valuation of SRPT can be described as very cheap.
  • Based on the Price/Forward Earnings ratio, SRPT is valued cheaply inside the industry as 98.64% of the companies are valued more expensively.
  • SRPT is valuated cheaply when we compare the Price/Forward Earnings ratio to 38.88, which is the current average of the S&P500 Index.
Industry RankSector Rank
PE N/A
Fwd PE 6.6
SRPT Price Earnings VS Forward Price EarningsSRPT Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 20 40 60 80 100

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
SRPT Per share dataSRPT EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 5 -5 10 15 20

4.3 Compensation for Growth

  • The low PEG Ratio(NY), which compensates the Price/Earnings for growth, indicates a rather cheap valuation of the company.
  • A more expensive valuation may be justified as SRPT's earnings are expected to grow with 29.84% in the coming years.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y50.1%
EPS Next 3Y29.84%

More info and screens

Price/EarningsPrice/FCFFCF per shareEV/EBITDAPEG RATIOShow best valued peers

0

5. SRPT Dividend Analysis

5.1 Amount

  • No dividends for SRPT!.
Industry RankSector Rank
Dividend Yield 0%

More info and screens

Find the best dividend stocksShow peers with best dividend

SRPT Fundamentals: All Metrics, Ratios and Statistics

SAREPTA THERAPEUTICS INC

NASDAQ:SRPT (4/22/2026, 8:00:01 PM)

After market: 20.52 -0.12 (-0.58%)

20.64

-0.04 (-0.19%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)02-25
Earnings (Next)05-04
Inst Owners89.82%
Inst Owner Change0.21%
Ins Owners5.13%
Ins Owner Change9.79%
Market Cap2.17B
Revenue(TTM)2.20B
Net Income(TTM)-713.41M
Analysts68.48
Price Target22.48 (8.91%)
Short Float %25.84%
Short Ratio9.06
Dividend
Industry RankSector Rank
Dividend Yield 0%
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)1
Avg EPS beat(2)-57.12%
Min EPS beat(2)-213.05%
Max EPS beat(2)98.8%
EPS beat(4)2
Avg EPS beat(4)-85.92%
Min EPS beat(4)-376.26%
Max EPS beat(4)146.84%
EPS beat(8)5
Avg EPS beat(8)217.73%
EPS beat(12)8
Avg EPS beat(12)382.89%
EPS beat(16)10
Avg EPS beat(16)274.39%
Revenue beat(2)2
Avg Revenue beat(2)13.2%
Min Revenue beat(2)10.8%
Max Revenue beat(2)15.59%
Revenue beat(4)4
Avg Revenue beat(4)11.58%
Min Revenue beat(4)6.86%
Max Revenue beat(4)15.59%
Revenue beat(8)7
Avg Revenue beat(8)7.41%
Revenue beat(12)10
Avg Revenue beat(12)6.28%
Revenue beat(16)13
Avg Revenue beat(16)4.84%
PT rev (1m)-27.3%
PT rev (3m)-25.73%
EPS NQ rev (1m)-9.16%
EPS NQ rev (3m)215.05%
EPS NY rev (1m)3.55%
EPS NY rev (3m)33.16%
Revenue NQ rev (1m)-1.01%
Revenue NQ rev (3m)26.07%
Revenue NY rev (1m)0.34%
Revenue NY rev (3m)11.67%
Valuation
Industry RankSector Rank
PE N/A
Fwd PE 6.6
P/S 0.99
P/FCF N/A
P/OCF N/A
P/B 1.9
P/tB 1.95
EV/EBITDA N/A
EPS(TTM)-6.65
EYN/A
EPS(NY)3.13
Fwd EY15.15%
FCF(TTM)-3
FCFYN/A
OCF(TTM)-1.96
OCFYN/A
SpS20.94
BVpS10.86
TBVpS10.59
PEG (NY)N/A
PEG (5Y)N/A
Graham Number0 (-100%)
Profitability
Industry RankSector Rank
ROA -21.3%
ROE -62.55%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM 69.33%
FCFM N/A
ROA(3y)-10.59%
ROA(5y)-13.51%
ROE(3y)-36.51%
ROE(5y)-67.48%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexgc growth 3YN/A
ROICexgc growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y-6.57%
GM growth 5Y-4.72%
F-Score3
Asset Turnover0.66
Health
Industry RankSector Rank
Debt/Equity 0.73
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr 246.73%
Cap/Sales 5%
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 2.32
Quick Ratio 1.48
Altman-Z -0.76
F-Score3
WACC8.47%
ROIC/WACCN/A
Cap/Depr(3y)277.68%
Cap/Depr(5y)204.92%
Cap/Sales(3y)6.58%
Cap/Sales(5y)5.88%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)-391.67%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-362%
EPS Next Y147.03%
EPS Next 2Y50.1%
EPS Next 3Y29.84%
EPS Next 5Y20.1%
Revenue 1Y (TTM)15.58%
Revenue growth 3Y33.07%
Revenue growth 5Y32.41%
Sales Q2Q%-32.73%
Revenue Next Year-18.84%
Revenue Next 2Y-17.93%
Revenue Next 3Y-12.16%
Revenue Next 5Y-7.26%
EBIT growth 1Y-325.82%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year197.86%
EBIT Next 3Y32.82%
EBIT Next 5Y17.55%
FCF growth 1Y10.61%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y0.15%
OCF growth 3YN/A
OCF growth 5YN/A

SAREPTA THERAPEUTICS INC / SRPT Fundamental Analysis FAQ

What is the ChartMill fundamental rating of SAREPTA THERAPEUTICS INC (SRPT) stock?

ChartMill assigns a fundamental rating of 2 / 10 to SRPT.


Can you provide the valuation status for SAREPTA THERAPEUTICS INC?

ChartMill assigns a valuation rating of 4 / 10 to SAREPTA THERAPEUTICS INC (SRPT). This can be considered as Fairly Valued.


Can you provide the profitability details for SAREPTA THERAPEUTICS INC?

SAREPTA THERAPEUTICS INC (SRPT) has a profitability rating of 1 / 10.


How financially healthy is SAREPTA THERAPEUTICS INC?

The financial health rating of SAREPTA THERAPEUTICS INC (SRPT) is 2 / 10.


What is the expected EPS growth for SAREPTA THERAPEUTICS INC (SRPT) stock?

The Earnings per Share (EPS) of SAREPTA THERAPEUTICS INC (SRPT) is expected to grow by 147.03% in the next year.